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Abstract 
 
Drug delivery agents for chemotherapy drugs have gained significant interest over the 
past few decades due to the need to localize the treatment to cancer cells. So far, polymeric 
micelles, liposomes, and carbon-based nanomaterials, among others, have shown great promise 
for this purpose. Starch nanoparticles have emerged as an avenue for drug delivery due to their 
low toxicity, biocompatibility and low cost. In this work, starch nanoparticles internally 
crosslinked by sodium trimetaphosphate (STMP) were prepared using a phase inversion 
emulsion process. From dynamic light scattering, transmission electron microscopy and 
environmental scanning electron microscopy, the particle size was determined to be 200-500 nm, 
regardless of STMP concentration used in the synthesis. 
31
P NMR determined that a wide variety 
of organic phosphates were present, apart from the desired phosphodiester crosslinking. These 
included triphosphates, monophosphates and diphosphates. In addition, like typical charged 
nanogels, these nanoparticles retained significant amounts of water when dispersed in solution. 
This was related to the electrostatic repulsion between the chains within the nanoparticle.  The 
presence of salt decreased the amount of water retention by screening of this electrostatic 
repulsion. The prepared nanoparticles were, in general, non-toxic to HeLa cancer cells. In 
addition, all prepared nanoparticles displayed a high drug loading, with a maximum seen with 30 
mol% STMP. This loading was higher at pH 7.6 compared to lower pH. Drug release occurred 
more readily at lower pH. Finally, it was seen that exposure to typical cell culture environments 
induced significant release of drug compared to simple buffer environments. 
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Chapter 1. Introduction 
 
Cancer is responsible for millions of deaths worldwide each year. In 2012 alone, there 
were 14 million new diagnoses and 8 million deaths as a result of the disease.
1
 Cancer is not 
simply one disease; it is a broad family of illnesses with one thing in common: the uncontrolled 
growth and proliferation of specific kinds of cells without apoptosis (or programmed cell death). 
Once this happens in a particular organ or tissue, the process continues. Eventually, the cells 
from that particular area may migrate to other organs and tissues, forming new tumors. This is 
known as metastasis and is the major reason why cancer is very difficult to treat.
1
 
Along with surgery and radiation treatment, chemotherapy is widely used in the treatment 
of cancer. This involves using cytotoxic drugs to directly kill the cancer cells. Several of these 
drugs vary in their mechanism of action. For example, doxorubicin, one of the main drugs, 
intercalates with DNA and is especially toxic to rapidly dividing cells (such as cancer cells).
2
 
Docetaxel, on the other hand, disrupts the process of cell division (also known as mitosis).
3
 
Docetaxel is much more hydrophobic compared to doxorubicin. One of the major limiting 
factors is that these drugs are non-discriminating; they affect both healthy and diseased cells. 
This leads to several debilitating side effects and inherently limits the dose that could be taken by 
an individual.
1
 In addition, many chemotherapeutics are carcinogenic and may induce their own 
cancers after continued use. There is therefore a need to localize chemotherapy to the site of 
action, sparing healthy cells. The drug must be protected to some degree until it is internalized 
into the cancer cell for immediate action.
4
 Towards this end, an entire field of research has been 
established to develop nanoscale materials for drug containment and delivery. 
2 
 
1.1 Drug Delivery Vehicles 
 
The idea of using designed vehicles to deliver drugs within the body has been 
investigated over several decades, with varying degrees of success.
5
 The growth of 
nanotechnology has been a major driving force for developing vehicles. Liposomes were one of 
the first structures to be implemented for drug delivery.
6
 Due to hydrophobic interactions of 
phospholipids in water and the cylindrical shape of the lipids, they self-assemble into a spherical 
bilayer structure. The small hydrophilic cavity is used for loading hydrophilic drugs. The first 
report of liposomes for drug delivery was in 1971, where Gregoriadis et al. successfully 
encapsulated an enzyme (an amyloglucosidase).
6
 Since that time, several liposome-based drug 
delivery systems have been studied and a few have completed clinical trials.
7–9
  One major issue 
of liposome-based drug delivery systems is their instability under various conditions of pH and 
salt concentration, and low loading efficiency as well as degradation by other molecules in the 
body.
10
 
Block copolymers are polymers containing multiple covalently-lined segments, each with 
a different structure. A common type is that one of the blocks is hydrophobic, while in the other 
type, one of the blocks is hydrophilic. In water, above the critical micelle concentration (CMC), 
these block co-polymers self-assemble to form micelles and the hydrophobic tails aggregate 
together to form a spherical domain. Masayuki et al. were among the first to use block co-
polymer based micelles to encapsulate an anticancer drug.
11
 In this study, they entrapped the 
hydrophobic drug, Adriamycin, with polyethylene glycol (PEG)-b-poly(aspartic acid) and 
observed the performance in vivo. Similar cell toxicity was seen when the drug alone was used, 
but the side effects from the use of polymeric micelles in rats were less pronounced, implying 
that the drug delivery was successful. Several studies have been done since then in the synthesis 
3 
 
and application of polymeric micelles for drug delivery, and one of the major issues is its low 
encapsulation efficiency without modification.
12,13
 
The synthesis and characterization of carbon nanotubes in the 1990s opened up a new 
avenue of research in nanotechnology in the form of carbon-based nanostructures.
14
 Later, more 
novel morphologies were found, such as graphene and carbon nanotubes. One main advantage of 
using carbon nanomaterials is the exploitation of physisorption for drug loading. Since drug 
molecules tend to be aromatic, they can stack favourably (due to π-π interactions) with the 
aromatic groups on the carbon nanomaterial surface.
15
 However, the potential for drug delivery 
was limited since these materials were not biocompatible and the toxicity was (and still is) under 
investigation.
16
  Several strategies have been implemented to make these materials 
biocompatible, namely functionalizing a biocompatible polymer or introducing hydroxyl groups 
on its surface. For example, Liu et al. were among the first to make carbon nanotubes 
biocompatible by functionalizing the surface with PEG.
17
 Exploiting the favourable π-π 
interactions, they were able to see a drug loading as high as 400% by weight (drug/CNT). 
Graphene (or more specifically, graphene oxide) has also demonstrated similar loading 
capabilities and applications in drug delivery.
18–20
 Besides toxicity, other issues are the cost and 
scalability of the synthesis, which would not lend itself to mass production.
21
 
Besides the three aforementioned systems, there are other nanoscale carriers currently 
under investigation such as metal nanoparticles,
22,23
 gels,
24,25
 and dendrimers.
26–29
 The 
progression of vehicles for drug delivery over time is shown in Figure 1. There are advantages 
and disadvantages for each carrier which limits their use in a clinical setting. The main 
parameters for each delivery vehicle are the cost, scalability of production and the performance 
(in vitro, in vivo and clinical).
5
 For newer systems, only preliminary research has been done and 
4 
 
several more years of work would be needed to demonstrate superior performance to current 
treatments. 
 
Figure 1. Progression of time for drug delivery vehicles.
9,30–32
 This does not reflect necessarily 
when these materials were developed, but mainly when they were utilized for drug delivery. All 
images reproduced with permission. 
1.2 Targeting Mechanisms 
 
In the context of drug delivery, one key limitation for success is ensuring proper 
specificity; only carrying the drug to the diseased cells and leaving healthy cells unaffected. To 
this end, two approaches have been employed: passive targeting and active targeting.
33
 For 
passive targeting, the nanocarrier loaded with drug would more likely accumulate in cancer cells 
than healthy cells due to abnormal growth and architecture coupled with a general lack of 
lymphatic drainage in the diseased cell. This is known as the enhanced permeability and 
retention (EPR) effect and is optimally seen in particles between 10 nm and 100 nm in size.
33
 
Once the particles aggregate within the tumor cells, their payload is ultimately released and the 
cancer cell dies.  
5 
 
Active targeting requires another step in the design of the nanocarrier: conjugation with a 
binding ligand. Most cancer cells have, on their surface, macromolecules (such as proteins) that 
will trigger internalization of an external agent within their cell walls through some binding 
event.
33
 These macromolecules are known as receptors and the process by which the external 
agent is internalized is known as receptor-mediated endocytosis.
34
 If a nanoparticle is conjugated 
with a ligand that binds to this receptor, the cell will internalize it. The receptors on the surface 
of a cancer cell will be present only for that type of cancer, allowing for selective targeting and 
sparing healthy cells. The ligand could be a protein, small molecule, or even DNA, as long as 
there is a significant binding event. 
Strictly speaking, active targeting is preferable to passive targeting since the ultimate 
internalization would depend more on the functionalization of ligand on the surface (which could 
be known, and controlled) compared to passive targeting, where more emphasis is placed on the 
cellular architecture and drainage (which may not be optimal, and is difficult to find out).
33
  
1.2.1 DNA Aptamers for Active Targeting  
 
Unlike proteins, which have been studied extensively for the active targeting of cancer 
cell receptors, DNA/RNA aptamers have only recently been studied for this purpose.
35
 This is 
because, until the late 1980s to early 1990s, there was no way to screen a large number of 
molecules for specific cell binding, isolate, and amplify the binding sequence.
36
 This is now 
possible through a process known as Systematic Evolution of Ligand by Exponential Enrichment 
(SELEX). SELEX was used initially to find DNA strands to bind to proteins in yeast,
37
 but has 
since been developed to detect various small molecules. To do this, it is necessary to start with a 
“DNA library”- a pool of random oligonucleotides (30-40 base pairs) flanked by two known 
6 
 
regions of nucleotides (between 15-20 base pairs).
38
 The two known regions are primers for a 
process known as polymerase chain reaction (PCR). PCR amplifies specific DNA sequences 
using an enzyme (usually the Thermus aquaticus polymerase) and thermal cycling from a few 
copies to thousands or even millions.
39
 The DNA library is incubated with the target molecule, 
and only oligonucleotides which have a certain affinity for the target (which are considered 
aptamer candidates) will bind. The unbound strands are separated and the bound strands are 
amplified using PCR. The amplified strands are then placed back into an environment containing 
the target and another round of selection is performed (with a selection pressure of reduced 
incubation time or target concentration).
38
 This process is repeated several times until suitable 
DNA aptamers are found.  Besides small molecules, DNA aptamers have been found that can 
bind to small molecules, metal ions, proteins, and even viruses.
40–42
 More recently, SELEX has 
been found to work for whole cells and is known as cell-SELEX.
43–45
 Most often, after finding 
the sequences that bind to the target cell, another step is added where a negative cell (i.e. a cell 
that is different to the target cell) is introduced into the selection.
44
 To tune the selectivity, those 
sequences that bind to the non-cancerous cells are removed from subsequent amplification and 
optimization process. 
There are several aptamers which have been found from cell-SELEX that have 
demonstrated specificity and high affinity for certain cancer cell lines.
46
  Some of these aptamers 
are summarized in Table 1. These aptamers are classed according which receptors they bind to, 
and not according to the cancer cells themselves. This is because many cancer cell lines may 
have similar receptors on their surface and would internalize the DNA aptamer in the same way. 
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Table 1. Selected aptamers developed by cell-SELEX 
Aptamer Target Reference 
AS1411 Nucleolin 
46,47
 
sgc8c Protein Tyrosine Kinase 7 (PTK7) 
46,48
 
5TR1 Mucin 1 (MUC1) 
46,49
 
A10 Prostate-Specific Membrane Antigen (PSMA) 
46,50
 
S11e Unknown (specific to A549 lung cancer cells) 
51,52
 
 
1.3 Starch as a Drug Delivery Vehicle 
 
Starch (or more specifically, starch nanoparticles) has emerged as a new drug delivery 
vehicle in recent years since its chemistry is very well studied, its behaviour is predictable and it 
is very biocompatible.
53–55
 Apart from being a carbohydrate that is widely found in many plant-
based foods, bulk starch has found some applications in industry. For example, starch can be 
used to make various sugars (such as glucose and dextrose) which are used as sweeteners in the 
beverage industry.
56
 Acid-modified starches (or hydrolysed starches) are used to lower the 
viscosity of the paste after cooking and are typically used in textiles.
57
 As it is used so 
extensively in food industries, starch is FDA-approved for a variety of applications. A 
comparison of drug delivery vehicles in terms of various necessary parameters are shown in 
Table 2. These parameters often determine whether a certain drug delivery vehicle is viable and 
none of these are necessarily more important than the other. 
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Table 2. A comparison of various drug delivery agents and their properties. 
Vehicle Cost Encapsulation 
Efficiency 
Stability Scalability Toxicity Reference 
Liposomes Low Low Low High Low 
10,58,59
 
 Polymeric 
Micelles 
Variable Low Low High Low 
60,61
 
Carbon 
Nano-
materials 
High High High Low Unknown 
16,17,62,63
 
Dendrimers High Variable High Low High 
64–66
 
Starch 
Nano- 
particles 
Low Moderate High High Low 
54,67,68
 
 
1.4 Primary and Secondary Starch Structure 
 
Starch is a polysaccharide derived from plants and is composed of two different 
polymers: amylose and amylopectin. The structures of these two polymers are shown in Figure 2. 
Amylose is simply a linear chain of glucose molecules linked together by a glycosidic bond, 
whereas amylopectin is significantly more branched. A glycosidic bond is one that occurs in 
carbohydrates where the 1-carbon of one glucose unit is linked to an anomeric carbon of another 
glucose unit. In the context of starch, glucose molecules are linked from the 1-carbon to the 4-
carbon (called a α (1→4) glycosidic bond).69 For amylopectin, branching takes place with a 
α(1→6) glycosidic bond, apart from the regular α (1→4) linkages.70 The ratio of these two 
polymers in the overall starch structure depends significantly on the source of the starch. For 
example, starch derived from corn contains 27% amylose and 73% amylopectin, whereas potato 
starch is composed of 20% amylose and 80% amylopectin.
69
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Figure 2. A comparison of (A) amylose and  (B) amylopectin.
71
 Amylose is a linear chain of 
glucose and can self-assemble into a helical structure. Amylopectin is a highly branched 
macromolecule where glycosidic bonds occur at the 6 carbon. Reproduced with permission. 
 
1.5 Granular (Bulk) Starch 
 
Starch is not soluble in water at room temperature and in fact, behaves like a suspension. 
This is because starch exists as granules that are typically several tens of microns in size.
69
 The 
internal structure of these granules can be quite complicated as shown in Figure 3. Models could 
be used to gain an idea of the arrangement of amylopectin and amylose within the starch granule. 
In general, there is a centralized region known as the hilium, with concentric rings of alternating 
amorphous and crystalline regions around it.
72
 Interestingly, while only amylose is capable of 
crystallization, crystalline regions in starch granules mainly consist of amylopectin (which, by 
itself, is not capable of crystallization). These crystalline domains stem from the oligosaccharide 
branches from the amylopectin with a chain length of approximately 23 glucose units and are 
10 
 
responsible for the crystalline “rings” within the granule.73 The amorphous region consists of the 
branching points of amylopectin with interspersed amylose. Water molecules are not able to 
penetrate these highly ordered structures at room temperature. However, if heated above a 
certain temperature while mixed with water, the water molecules are able to penetrate the starch 
granules, causing them to swell.
69
 Eventually, after heating for a certain amount of time the 
granules rupture, break apart, dissolve and release amylose and amylopectin chains. The amylose 
chains align to form a network, resulting in a significant increase in viscosity.
74
 At this point, the 
water molecules act as a plasticizer for this crosslinked network and the starch is considered to 
be “dissolved”. This entire process of starch gelatinization in water is known as cooking and is 
one of the main reactions performed to make starch soluble. It should be noted that this 
gelatinization can occur almost spontaneously in alkaline conditions (more specifically, pH>10) 
without significant heating due to increased rate of hydration of the granules.
69
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Figure 3. Growth ring model and chain distribution model to explain starch granule structure.
72
 
In general, there are areas of alternating amorphous and crystalline regions which self-assemble 
to form large granules. Reproduced with permission. 
 
 
1.6 Crosslinking of Starch 
 
Depending on the application, it may be necessary to increase resistance to shear stress 
for typical processing applications.
75
 A hydroxyl group on starch could, through some basic 
chemistry, be linked to another hydroxyl group from another starch chain with a bifunctional 
small molecule. This results in the formation of a crosslink between the two chains. Crosslinking 
smaller starch particles provide more stability and resistance to degradation. Several molecules 
have been used to crosslink starch in the past, such as glyoxal
76
, sodium trimetaphosphate 
(STMP),
77
 sodium tripolyphosphate (STPP),
77
 citric acid,
78
 and epichlorohydrin.
75
 While 
epichlorohydrin by itself has shown evidence of reproductive toxicity,
79
 the crosslinking reaction 
12 
 
forms “glycerol bridges”, which are considered non-toxic. Citric acid could be used but the 
crosslinking method involves using harsh conditions, and is time consuming.
78
  
1.6.1 STMP Crosslinking 
 
STMP is a biocompatible and non-toxic crosslinker regularly used for starch. It consists 
of three phosphate groups arranged in a cyclic manner, with alternating phosphorus and oxygen 
atoms completing a 6-membered ring. It is a FDA-approved thickening agent and, like most 
cross-linkers for starch, it provides more mechanical stability to shear in food processing.
69
 The 
overall reaction scheme for the crosslinking of starch by STMP is shown in Figure 4. At a 
sufficiently high alkalinity (pKa for hydroxyl groups ~12.6
80
), the hydroxyl groups on the sugar 
rings become deprotonated (forming an alcoholate) and the oxygen ion can attack one of the 
phosphorus atoms on the ring through a nucleophilic reaction mechanism. Another hydroxyl 
group on starch would attack the same phosphorus atom, forming a phosphate bridge between 
the two sugar rings. 
 
Figure 4. Overall reaction scheme for starch crosslinked by STMP. A phosphorus atom on the 
STMP ring will undergo nucleophilic attack by a starch alcholate group, forming a triphosphate. 
13 
 
Another starch alcholate will attack the same phosphorus atom, forming a distarch 
monophosphate. 
In reality, the crosslinking reaction is much more complicated, and it is somewhat 
inefficient. Sang et al. performed extensive 
31
P-nuclear magnetic resonance (NMR) studies to 
determine the extent to which side reactions may dominate the crosslinking reaction.
81
 A 
summary of the proposed reactions is shown in Figure 5. The first step of the reaction is the 
nucleophilic attack of the starch alcholate on the STMP ring to form monostarch triphosphate. At 
this point, two different reactions may occur if the pH is maintained between 11.5 and 12.5. The 
first is with another starch alcholate attacking the same phosphorus forming the desired crosslink 
(distarch monophosphate). The second reaction that may occur is with a hydroxyl group 
(supplied by alkaline conditions) attacking the same phosphorus, forming monostarch 
monophosphate, which is quite stable. Lastly, a peeling reaction can occur at lower pH where a 
phosphate group from the monostarch triphosphate can migrate off, eventually (in the presence 
of water) forming the HPO4
2-
 anion. These findings were also supported by Lack et al., who 
performed similar studies using a model system and arrived at a similar conclusion.
82
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Figure 5. Detailed mechanism for starch crosslinking by STMP. Figure derived and redrawn 
from Sang et al.
81
 Reproduced with permission. 
Only 50% of the STMP added initially actually reacts with starch to form the 
triphosphate. Of that amount, ca. 20% goes on to form the distarch monophosphate (the other ca. 
80% being various other phosphate species, including triphosphates and pyrophosphates).
82
  
Therefore, with respect to the amount of STMP that is added, the reaction itself is relatively 
inefficient. The addition of salts (such as sodium chloride) is known to increase the efficiency of 
the reaction,
83
 most likely due to increased screening of the charges of the negatively charged 
phosphate groups, allowing for more nucleophilic attack.
77
 The kinetics of the crosslinking is 
typically quite slow at room temperature and crosslinking of bulk starch may take days.
77
 This 
crosslinking process is also temperature dependant, with higher temperatures being shown to 
result in more phosphorus incorporation.
84
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1.7 Starch Nanoparticles for Drug Delivery 
 
Bulk starch would not be useful for applications like drug delivery since the size of the 
granules are simply too big. Therefore, a great deal of interest has been placed in making starch 
particles on the nanoscale. To that end, there are several processes which have already made 
strides in this field and which can be placed into three classes: hydrolysis, regeneration and 
mechanical treatment.
85
  
Hydrolysis is a common reaction in which water is used to break a chemical bond.
86
 In 
polysaccharides, such as starch, this reaction normally would take place at the position of the α 
(1->6) glycosidic bond in amylopectin and is normally performed using strong acids.
87,69
 More 
recently, this method has been used to make crystalline starch nanoparticles.
85
 Many studies have 
confirmed this behaviour and the size of the nanocrystals appeared to depend on the source of the 
starch, but generally was between 10-80 nm in size.
88,89
 In these cases, the acid was able to 
dissolve the amorphous regions of starch, leaving crystalline nanodomains present. The 
crystallinity was confirmed by X-ray diffraction studies. Amylase, an enzyme which degrades 
starch, was also reported to form 500 nm nanocrystals through hydrolysis.
90
 
Regenerative methods of producing starch nanoparticles (SNPs) include precipitation, 
reactive extrusion, and cocrystallization
85
. For example, Kim and Lim utilized the property of 
complex formation between amylose and polar lipids (in this case, butanol) and combined it with 
enzymatic hydrolysis to form starch nanocrystals of sizes between 28-51 nm with very low yield 
amounts (ca. 1%).
91
 EcoSynthetix, a company based in Burlington, ON, have used a proprietary 
reactive extrusion technique to make starch-based biopolymer latex nanoparticles.
92
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Nanoprecipitation has also been used to make starch nanoparticles, as well as other 
polymeric nanoparticles.
93–95
 With starch, crosslinking of the particles was performed using 
STMP or sodium tripolyphosphate (STPP). STPP is similar to STMP in that a phosphate linkage 
is formed between the two starch chains, but the mechanism is slightly different.
77
 In some of 
these studies, the ultimate application was drug delivery, which provides an idea of the state of 
the field.  For example, Nagger et al. synthesized STPP-crosslinked starch nanoparticles of sizes 
less than 60 nm using TWEEN 80 as a surfactant.
96
 They encapsulated a non-steroidal anti-
inflammatory drug (NSAID), diclofenac sodium (DS), and observed an optimal entrapment 
efficiency of 95%, with the release being modulated by the amount of crosslinking present. The 
ultimate application was transdermal drug delivery. Narayanan et al. used nanoprecipitation to 
synthesize STMP crosslinked hydroxyethyl-starch nanoparticles and loaded two NSAIDs, 
ibuprofen (IB) and indomethacin (ID), within the starch particles.
67
 In this study, the 
precipitation was carried out in methanol (stabilized with lecithin) and crosslinking was 
performed for 3 hours at 47 
o
C in alkaline conditions. Particle sizes were ca. 150 nm in water and 
slightly higher in phosphate buffer saline (PBS). Little in-vivo toxicity was seen in rats and the 
encapsulation efficiency for IB and ID were ca. 75.41% and ca. 77.38% respectively. 
Lastly, mechanical agitation has been utilized to form starch nanoparticles. This agitation 
could be provided by ultrasonication, high shear mixing, or high pressure 
homogenization/microfluidization.
85,97
 Shi et al. used high pressure homogenization combined 
with an emulsion to produce STMP-crosslinked particles of sizes between 100-300 nm.
98
 In this 
particular method, the emulsion droplets served as a reaction vessel for the crosslinking to occur 
and parameters that determined particle size were surfactant concentration, starch concentration, 
passes in homogenizer, pressure, as well as the ratio of dispersed phase/continuous phase. Xiao 
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et al. conjugated SNPs with folic acid (FA)-polyethylene glycol (PEG) using an emulsion-based 
method and crosslinked them using POCl3.
99
 Folic acid is able to be internalized more selectively 
by cancer cells as they have an overabundance of folic acid receptors. They were able to see a 
maximum doxorubicin drug loading of 25 µg/mg SNPs and observed higher internalization of 
the FA-PEG-SNPs inside cancer cells compared to normal cells. However, beyond this study, 
there have been very few reports of SNPs specifically for drug delivery into cancer cells. 
1.8 Previous Work from the Liu Lab-ECO collaboration 
 
In the past, Howard Tsai of the Liu lab investigated the efficacy of starch-based, 
experimental grade biopolymer latex nanoparticles (BLNPs) supplied by EcoSynthetix, for drug 
delivery. These particles, prior to any chemical modification had had a dominant particle size of 
~20-150 nm and were easily dispersed in water.
92,100
  It would be difficult to observe any uptake 
of the BLNPs into cancer cells, and so functional molecules such as dye or dye labelled DNA 
were conjugated on the surface of the particles. The uptake of the BLNPs in cancer cells was 
visualized using confocal microscopy. 
1.8.1 Cellular Uptake 
 
BLNPs were conjugated with both dye and dye-labelled DNA aptamers for visualization 
of the uptake in “Henrietta Lacks” (HeLa-a cervical cancer cell line) cells using confocal 
microscopy. The AS1411 aptamer was chosen as it has an affinity to nucleolin, a protein found 
overexpressed on many cancer lines (including HeLa). Confocal images of functionalized BLNPs 
in cells are shown in Figure 6. The nuclei of the cells are labelled with 4',6-diamidino-2-
phenylindole (DAPI), which stains DNA inside the nucleus and is shown in the blue channel. 
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The cytoplasm of the cell is typically stained with a fluorescein labelled phalloidin, which binds 
strongly to actin inside cells and seen below in the yellow channel.  In this case, the BLNPs were 
stained with a green fluorescein isothiocyanate (FITC) dye and the aptamer was labelled with a 
red dye (usually a rhodamine derivative). Internalization of dye-labelled BLNPs was seen, even 
without conjugated aptamer. This could be attributed to the EPR effect mentioned before, where 
smaller particles tend to accumulate in cancer cells as a means of passive targeting. Once 
aptamers were functionalized on the surface of the particle, no significant increase in the 
internalization was seen, even with higher amounts of aptamer. The dye fluorescence on the 
green channel was co-located with the red fluorescence on the red channel, confirming that the 
DNA aptamers and the dye were located on the particles. 
 
Figure 6. Confocal microscopy of loaded BLNPs in HeLa cells.
101
 Experiments performed by 
Tsung-Hao Tsai. Reproduced with permission. 
 
As a comparison, aptamer and dye-loaded liposomes were synthesized and compared to 
the BLNP uptake. Liposomes, as discussed before, are among the oldest known drug delivery 
vehicles and are well understood. The confocal images of the uptake are shown in Figure 7. 
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Conjugated liposomes appear to be internalized by the cells significantly more than the BLNPs, 
even at fairly high DNA concentrations for loading of the BLNPs.  
 
Figure 7. Comparison of BLNPs and liposome internalization.
101
 Experiments performed by 
Tsung-Hao Tsai. Reproduced with permission. 
1.8.2 Limitations of BLNPs for Drug Delivery 
 
To attempt to explain why the BLNPs directly received from EcoSynthetix were not very 
suitable for cell internalization (and by extension, drug delivery), it is necessary to consider the 
size of the particle, as well as the nature of internalization itself. When aptamers bind to 
receptors on the cell surface, the process of internalization begins where cell membrane collapses 
to engulf the particle in a vesicle, pushing it into the cytoplasm. This internalization is known as 
receptor-mediated endocytosis. This phenomenon is promoted by the multi-valence effect, where 
the more aptamer on the surface of the particle, the stronger the binding will be and the more 
internalization will occur.  
As mentioned before, the particle size of the BLNPs was between 20-50 nm. Liposomes 
may have variable size but in drug delivery, typical diameters are between 100-200 nm.
102
 By 
virtue of surface area alone, there would be much higher coverage of DNA on each liposome 
compared to the BLNPs, as shown in Figure 8. One possible solution would be to use more DNA 
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aptamers to get more coverage on the surface of the BLNP. However, this is not very cost-
effective. If the assumption is made that the BLNPs molecular weight (MW) is 1000000 g/mol 
(based on the molecular weight of amylopectin), and the MW of the DNA aptamer is known to 
be ca. 10000 g/mol (for a 30 nucleotide aptamer), then 8 aptamers on the surface of the particle 
would already be 8% of the MW of the BLNP (as an example). In a 100 nm liposome, the MW is 
ca. 76000000 g/mol. If we keep the same density for the BLNPs, from previous research, 200 
aptamers would attach to the surface of the liposome
103
. Therefore, this corresponds to just 2.6 % 
of the molecular weight of the liposome. In a 1:1 molar ratio of BLNPs/liposome:DNA, for every 
gram of BLNP that is used, 10 mg of DNA aptamer is used, whereas for a liposome, ~131 µg is 
used. This corresponds to using ~76 times more DNA to get a similar loading in BLNP, 
compared to a liposome. DNA is significantly more expensive than starch, and therefore, by 
simple scaling, it would be 76 times more expensive to use BLNPs compared to liposomes. 
Another aspect of the small particle size lies in the drug loading capacity. In the long run, 
drugs would be loaded into the porous starch structure. Previous drug loading studies with these 
nanoparticle showed that the loading capacity was only 0.054%. If each particle was assumed to 
be spherical, then a small sphere such as the BLNP would have a certain drug loading within it. 
Evidently, this drug loading is limited by the volume and thus would be a function of the radius 
of the sphere. If the radius of the sphere were to be increased by 10, then the volume would 
increase by 1000-fold (volume scales to the third power of radius). Subsequently, the drug 
loading would increase by 1000-fold as well. Ignoring the cost of the vehicle itself, the main 
factor to consider (economically) is how many drug molecules each aptamer may carry. In that 
regard, the drug/aptamer ratio becomes important. Aptamer coverage on the BLNP surface is 
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limited by surface area, while drug loading is limited by volume. Therefore, increasing the 
particle size by 10-fold would increase the drug/aptamer ratio by 10 fold by simple scaling. 
The ideal SNP would be in the range of 80-300 nm, with a high molecular weight so that 
more drug molecules could be loaded into porous starch structure, and for more aptamer 
coverage to exploit the multi-valence effect in cellular uptake. It must still be small enough to be 
internalized into the cell in the first place, and should ideally be smaller than 300 nm. 
Nanoparticles that are too large are easily cleared by the body. Modification with STMP would 
also add a highly negative charge to the particle and potentially further improve the drug loading 
capacity. 
 
Figure 8. Limitations of non-crosslinked BLNPs for targeted drug delivery. Low surface 
coverage of DNA aptamer and potentially low drug loadings provide evidence for the need of a 
larger particle. Picture of liposome reproduced with permission.
104
  
1.9 Research Goal and Implementation 
 
With all the previous work in mind, the challenge lay in making larger starch 
nanoparticles for purposes of drug delivery as outlined in Figure 9. Free starch chains would be 
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crosslinked by STMP in a controlled manner to form high MW particles to satisfy the 
requirements from previous studies, followed by conjugation with DNA aptamer for cell-
internalization studies. Ideally, these new nanoparticles would have a superior performance the 
BLNPs studied previously. 
 
Figure 9. Confining crosslinking of starch chains to form nanoparticles followed by conjugation 
with DNA aptamer. 
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Chapter 2. Synthesis and Characterization of Phosphate Crosslinked Starch 
Nanoparticles 
 
2.0 Introduction 
 
To confine the particle size to sub-micron regimes, emulsions (more specifically, W/O 
emulsions) could be used, as discussed previously. Since the STMP is hydrophilic, it will 
partition into the water phase. The size of the particle is determined by the droplet size during the 
emulsion process as the particles would be internally crosslinked within it. Without access to 
powerful mixers (such as high pressure homogenizers and high-power ultrasonicators), W/O 
emulsion droplets are mostly confined to sizes greater than 1 μm.105 Despite this, several low-
energy approaches have been found to produce nanoemulsions (emulsion droplets with size 
between 20 and 500 nm). One of these approaches, phase inversion emulsions (PIEs), have 
attracted some interest in recent years due to its ease and scalability.
105–107
 
Typically, if one were to homogenize a mixture of a water phase and an oil phase in the 
presence of a surfactant, an emulsion is formed where one phase (the dispersed phase) is 
suspended in the other phase (the continuous phase) as droplets. The resulting emulsion formed 
can be oil-in-water (O/W) or water-in-oil (W/O) depending on the type of surfactant used. For 
example, if a hydrophilic surfactant is used, an O/W emulsion can be made. The opposite is true 
for a hydrophobic surfactant. Hydrophilicity of a surfactant is determined by the hydrophile-
lipophile balance (HLB), which has a value between 0 (extremely hydrophobic) to 20 (extremely 
hydrophilic).
108
 A general rule of thumb is that a surfactant with HLB > 10 will typically 
stabilize an O/W emulsion at room temperature and one with HLB < 10 will stabilize a W/O 
emulsion. 
24 
 
As mentioned previously, a hydrophilic surfactant could be used to prepare an O/W 
emulsion. However, non-ionic surfactants which are hydrophilic at room temperature may not 
retain this behaviour at higher temperature. In fact, many of these surfactants become 
significantly more hydrophobic with increasing temperature. This is due to the dehydration of the 
polar hydroxyl head groups, effectively weakening the interaction of the surfactant with 
water.
109,110
 The HLB decreases and the surfactants become more lipophilic. Therefore, heating 
an aqueous solution containing a hydrophilic surfactant would eventually cause the solution to 
turn cloudy and phase separate from the water. This is called the cloud point of a surfactant and 
is influenced by a variety of factors. Increasing salinity or adding alcohol causes the cloud point 
to change as it further interferes with the polar interactions of the water molecules and the head 
group of the surfactant. 
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In an O/W emulsion stabilized by these non-ionic surfactants, the O/W emulsion 
becomes a W/O emulsion at higher temperature in a process known as phase inversion as shown 
in Figure 10. The temperature at which the phase inverts is known as the phase inversion 
temperature (PIT). At T<PIT, the O/W droplets are stabilized in solution by the surfactant. Once 
T=PIT, the surfactant becomes sufficiently hydrophobic that it does not necessarily stabilize one 
phase vs the other and the result is a bi-continuous phase within the initial oil droplet. At T>PIT, 
the surfactant becomes even more hydrophobic and would stabilize a W/O emulsion more 
readily. The droplet size of the resulting W/O emulsion is typically much less than the initial 
O/W emulsion because the phase inversion is constrained within each individual droplet. In fact, 
nanoemulsions (emulsions with droplet size <100 nm) have been reported using this phase 
inversion principle by lowering the temperature after an initial phase inversion.
112
 However, 
these nanoemulsions were O/W, and therefore not useful for the STMP-SNP synthesis. 
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Figure 10. Concept of phase inversion emulsion. Certain anionic surfactants become more 
hydrophobic with temperature resulting in an inversion of a W/O emulsion to an O/W emulsion. 
For SNP synthesis using phase inversion, the basic concept is shown in Figure 11. In 
brief, an oil phase is homogenized with a water phase containing fully cooked starch. Once the 
O/W emulsion forms, the temperature is raised to a temperature greater than the PIT for the 
particular surfactant and reaction conditions used. Once the phase inversion has completed, 
STMP would be added and the reaction would be allowed to proceed for 1 hour, forming 
internally crosslinked nanoparticles. EcoSynthetix, the collaborating company for this project, 
owns a patent where they describe the exact protocol for the formation of starch nanoparticles 
using this process.
107,113
 Paraffin oil was used as the oil phase, with Tween 85 used as the 
surfactant. Tween 85 is an anionic surfactant with a critical micelle concentration (CMC) of 0.09 
mM and a HLB of 11.
114,115
 As such, it is already relatively hydrophobic (compared to other 
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hydrophilic stabilizers) but will initially form an O/W emulsion at low temperatures. To decrease 
the phase inversion temperature further, 0.3 M NaCl was used. Apart from this function, NaCl is 
a known catalyst of the STMP crosslinking reaction as it screens electrostatic repulsion of the 
phosphates for nucleophilic attack.
107
 As reported by the patent, the phase inversion temperature 
of this emulsion is 25
o
C. Slight modifications were made to this procedure to optimize the 
amount of STMP needed to induce nanoparticle formation, leaving the parameters responsible 
for phase inversion (Tween 85 concentration, NaCl concentration, and volume fractions of oil 
and water phase) constant.  
  
 
Figure 11. Schematic for STMP-SNP synthesis using PIE. Initially, an O/W emulsion is formed 
which, after an increase in temperature, becomes an O/W emulsion. The STMP is added so that 
the crosslinking reaction occurs within the emulsion droplet. 
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2.1 Materials and Methods 
 
Cooking of Starch Granules. Typically, 46.8 g of waxy maize starch was dispersed in 1 
L of deionized water. To this mixture, 20.8 g of NaCl and 11.7 g of NaOH was added, and the 
whole was brought to 55
o
C for 2 hours. The solution was allowed to cool and stored at 4
o
C until 
ready for use. 
PIE for STMP-SNP Synthesis. In a typical reaction, 35 g of Tween 85 was dispersed in 
600 mL of paraffin oil (oil phase) using a Silverson L4H high shear mixer stirring at 3000 RPM. 
Once the surfactant was fully dispersed, 400 mL of the cooked starch/NaCl solution in NaOH 
(water phase) was added and the shear rate was increased to 7500 RPM to form the emulsion. 
The temperature after complete homogenization of water and oil phase was ~18
o
C. The shear 
force acting on the emulsion was enough to increase the temperature significantly, without any 
external heating required. At 55
o
C, STMP was added in solid form at various concentrations to 
initiate the crosslinking reaction. The amount of STMP added was varied with respect to the 
amount of starch in the reaction. More specifically, it was expressed as a mole percentage of the 
anhydroglucose units (AGU) of starch used in the reaction. Taking 5 mol % STMP as an 
example, there would be 5 STMP molecules for every 100 AGU in starch. To calculate the mass 
of STMP to be added the following formula was used 
𝑚𝑆𝑇𝑀𝑃 = 𝑋 ∗
𝑛𝐴𝐺𝑈
100(1 − 𝑋)
∗ 305.885
𝑔
𝑚𝑜𝑙
 
Where mSTMP was the mass of STMP to be added, X was the desired mol % STMP, nAGU 
was the number of moles of AGU (MWAGU=162 g/mol) used and 305.885 g/mol is the molecular 
weight of STMP. Samples were synthesized using different values of X: 0, 1, 5, 10, 30 and 50 
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mol% STMP. The STMP would partition in the water phase as it was completely insoluble in the 
oil phase. The reaction was then allowed to proceed for 1 hour at 70
o
C.  
To stop the reaction, 3 g of 37% HCl was diluted in 200 mL water and added to the 
emulsion. This neutralized the basic water phase so that nucleophilic attack of the starch 
hydroxyl groups to the STMP would be minimized and the crosslinking reaction stopped. The 
temperature was then brought down to 20
o
C so that the continuous phase is aqueous (reversion to 
O/W emulsion). The particles were then precipitated using ethanol. To remove surfactant, the 
precipitate was washed three times with absolute ethanol and filtered using Buchner filtration. 
The nanoparticles were then dispersed in water and placed in a separatory funnel and allowed to 
stand so that oil could partition to the top of the dispersion. The water phase was then collected 
and any remaining oil was set aside for recycling. This was repeated 3 times to ensure any oil 
was removed. Finally, the sample was placed inside 10 kDa MW cut-off membrane for dialysis 
in a 1:10 ratio to dialysate to remove phosphate and chloride salts. Initially, the sample was 
dialyzed against 10 mM NaCl dialysate to lower the concentration gradient of salt from inside 
the membrane. This would prevent too much water from entering the membrane and rupturing it. 
It was then lowered by increments of half until day 4, when no salt was added. Dialysis was 
continued for 6 days, with initial dialysate changes occurring every 3 hours. After day 3, the 
dialysate was changed twice per day. Once dialysis was complete, the sample was frozen and 
stored at -20
o
C for lyophilisation. 
Dynamic Light Scattering and ζ-Potential. In a typical measurement, 1 mg STMP-
SNPs were dispersed in 1 mL milli-Q water (final concentration: 1 mg/mL) and placed in a low-
volume disposable sizing cuvette for measurement in a Malvern Zetasizer (Nano series). For ζ-
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Potential, 1 mg of STMP-SNPs were dispersed in 1 mL 50 mM HEPES buffer  (pH 7.6) and 
placed in a disposable zeta-cell for measurement. All measurements were performed at 25
o
C. 
 TEM. The sample was prepared by dispersing 1 mg STMP in 1 mL water (final 
concentration= 1 mg/mL) before placing 15 μL on a holey carbon grid and allowed to dry 
overnight. The next day, the samples were imaged using a Phillips CM-10 electron microscope. 
 ESEM. A small amount of freeze-dried powder from the 0 mol% and 10 mol% samples 
were placed on an SEM sample holder with carbon tape. Compressed air was blown on the 
sample to remove loosely bound powder so that optimal imaging could be performed. The 
imaging was performed on a FEI Quanta Feg 250 ESEM. 
 
31
P NMR. STMPs were dispersed in 1 mL milli-Q water at a concentration of 15 mg/mL 
and transferred to an NMR-tube. The proton-decoupled measurement was performed in an 
Avance 500 NMR spectrometer operating at 500 MHz (
1
H) and 202 MHz (
31
P) using phosphoric 
acid as a reference and without a solvent lock. All samples were run with a delay of 5 seconds, a 
pulse width of 2.8 seconds and a sweep width of 398.35 ppm. 
 Water Retention Studies. STMP-SNP samples prepared with different mol % STMP 
were dispersed in 1 mL water at a concentration of 15 mg/mL in a micro-centrifuge tube. These 
tubes were pre-weighed before the solution was placed in the tube. The samples were then 
centrifuged at 15000 RPM for 20 minutes. After centrifugation, supernatant was removed and 
the tube was re-weighed with the swollen product. The mass of the tube recorded before the 
experiment, as well as the mass of SNP present (15 mg) was subtracted from the final recorded 
weight to find the amount of water retained. For studies with salt, the sample which yielded the 
highest water retention (30 mol% STMP) was dispersed at a concentration of 15 mg/mL in 1 mL 
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water in various pre-weighed tubes. Two salts (NaCl and MgCl2) were then added at increasing 
concentrations. The samples were then centrifuged, the supernatant decanted, and weighed. 
2.2 Results and Discussion 
 
During the synthesis, several characterization techniques were performed to ensure that 
the intended processes were occurring. These included polarized light microscopy to ensure 
cooking of starch, optical microscopy to determine droplet size and conductivity measurements 
to determine the phase inversion temperature of the emulsion. In addition, several 
characterization methods were employed to determine the physical and chemical properties of 
the prepared STMP-SNPs. These include: dynamic light scattering (DLS), transmission electron 
microscopy (TEM), scanning electron microscopy (SEM), 
31
P nuclear magnetic resonance 
(NMR) spectroscopy, ζ-potential, and water retention studies. 
2.2.1 Synthesis of STMP-SNPs 
First, complete cooking of starch needed to be confirmed before the PIE procedure could 
be initiated. If there were any bulk starch granules left in the water phase, crosslinking would 
occur from the granule, resulting in a significant increase in particle size. The complete 
dissolution of starch was confirmed by light microscopy in Figure 12 with (A) and without (B) 
polarizers. If crystalline domains (such as those found in starch granules) were present, they 
would interact with polarized light giving rise to contrast from the background. No evidence of 
starch granules were seen after 2 hours of cooking as there appeared to be no granules left to 
interact with the polarized light.  
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Figure 12. Light microscopy of cooked starch with (A) and without (B) crossed polarizers.
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Since there was no signal present with the polarizers, no crystalline granule regions were present; 
the starch was fully cooked. 
 
As mentioned previously, Tween 85 was the stabilizer used for this emulsion and its 
chemical structure is shown in Figure 13. The four polar polyethylene glycol heads serve as the 
hydrophilic stabilizer, while the three fatty acid tails serve as the hydrophobic stabilizer. 
Compared to many other Tween-based surfactants, it is quite hydrophobic and would just barely 
stabilize an O/W emulsion at room temperature.  
 
Figure 13. Chemical structure of Tween 85. 
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2.2.2 Characterization of Phase inversion 
 
To characterize the emulsion process, two methods were employed: conductivity and 
light microscopy. The former was to confirm phase inversion from O/W to W/O and the latter 
was to determine the droplet size. Before phase inversion, water would be the continuous phase 
and as such, any conductivity measurement would yield a high value. This is especially true 
since there were NaCl and NaOH present, which facilitates current flow. On the other hand, after 
phase inversion, oil would be the continuous phase. Since there were no ions present in the oil 
phase, the conductivity would drop significantly upon phase inversion. Using this principle, the 
conductivity was measured as a function of temperature, as shown Figure 14. Before ~30
o
C, the 
conductivity was high (~11 mS/cm) as water was the continuous phase. Beyond this temperature, 
there was a rapid drop in conductivity to ~100 μS/cm, correlating to the phase inversion of the 
emulsion.  In addition, consistency of the emulsion changed significantly after phase inversion; 
below the PIT, the emulsion appeared thick and viscous whereas beyond the PIT, it appeared 
much thinner. 
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Figure 14. Conductivity measurements during phase inversion. A clear drop in conductivity is 
seen starting at 30
o
C, indicating the phase inversion process had begun. Once it levelled off, the 
process was complete. 
The droplet size was characterized before (A) and after (B) phase inversion using optical 
microscopy as shown in Figure 15. Before phase inversion, droplet sizes were between 2-8 μm. 
After phase inversion, it was impossible to determine the droplet size as they were beyond the 
limits of the optical microscope resolution. 
 
Figure 15. Optical microscopy of emulsion droplets before (A) and after (B) phase inversion. 
There was a very apparent decrease in droplet size after phase inversion, which could not be 
resolved from optical microscopy. 
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2.2.3 DLS and ζ-Potential 
 
 Dynamic light scattering (DLS) is used to measure the size of particles in solution.
116
 In 
principle, a sample is illuminated by a laser light and the amount of scattering is detected. For a 
very small time period after an initial measurement, the amount of scattering will be the exact 
same as the time period before it. It could therefore be said that at that time period, there is a full 
correlation between the two measurements. However, as time increases, this correlation will 
decrease due to the movement of particles by Brownian motion. Assuming full correlation 
corresponds to “1” and no correlation corresponds to “0”, a correlation function could be 
generated, which is normally in the form of an exponential decay.
117
 Smaller particles move very 
quickly, and therefore the correlation function would decay to zero at a short time period after 
measurement begins. Larger particles move much more slowly and therefore the correlation at 
higher time periods would decay to zero at longer times after the beginning of the measurement. 
In an ideal case, the correlation function can be modeled by an exponential function, where a 
relaxation time could be obtained for a particular species in solution. This relaxation time is 
related to the diffusion coefficient of the particulate species in solution. Using the Stokes-
Einstein equation, and known parameters like temperature and viscosity, the hydrodynamic 
radius could be obtained. This is done automatically by the instrument software and what is 
obtained is an intensity plot is generated from the correlation function which provides an idea of 
the population of particle sizes in solution.  
 In addition to DLS, ζ-potential measurements were also performed on the STMP-SNPs 
prepared. If a charged particle is in solution, then it will attract counter ions to its surface via 
coulombic interactions. This layer of counter ions is called the Stern layer. The concentration of 
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these counter ions decays with distance away from the particle and, this region is known as the 
diffuse layer.
118
 Collectively, the Stern layer and the diffuse region are part of the electrical 
double layer. At a certain point, there is no excess of one ion over the other, which corresponds 
to the bulk liquid phase. However, some of these solvated counter ions move with the particle 
itself and are considered to be “attached” to the particle. The point in the electrical double layer 
where this “attachment” stops is known as the slipping plane. In principle, the ζ-potential 
measures the difference in electric potential between bulk liquid and the slipping plane. From 
this, information about the particle surface charge can be obtained.
118
 
 The intensity distribution of hydrodynamic diameter measured from DLS for samples 
prepared using different amounts of STMP is shown in Figure 16 A. Without STMP, the free 
starch chains appeared to have a hydrodynamic diameter between 30-40 nm. Normally, a high 
MW polymer such as starch would have a larger hydrodynamic radius in solution. However, 
exposure to shear forces used in the process would have likely reduced the size of the native 
starch chains (resulting in a lower hydrodynamic radius). When STMP was used, this diameter 
increased to between 300-400 at 30 and 50 mol%. In between these two extremes, there appeared 
to be a progression in the particle size from smaller to larger. This is unlike typical crosslinked 
nanoparticles, where there is a general decrease in particle size with crosslinker content. This 
increase was therefore likely due to the crosslinking of the starch chains within the emulsion 
droplets, resulting in a particle limited by the size of the droplets. Based on the sizes obtained at 
high STMP concentrations, it appeared that these droplets (and as such, the particles sizes) were 
between 200-400 nm. At lower concentrations, it was possible that less crosslinking was 
occurring and this limited the particle size to less than the droplet size. Apart from crosslinking, 
the mixture is being subject to very high shear forces which could also affect the particle size. 
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Such forces, in such conditions of pH and temperature, could be enough break the starch chains 
to smaller lengths, resulting in lower hydrodynamic radii (especially evident at lower STMP 
content). 
 The ζ-Potential measurements for each sample in pH 7.6 50 mM HEPES buffer is shown 
in Figure 16 B. There was a general increase in the negative surface charge of the particles with 
STMP concentration. Even at 1 mol % STMP, there was a great deal of negative charge imparted 
on the particles. Quite likely, there was some phosphorylation at lower STMP concentrations but 
the nature of these species was dominated by phosphates that were not necessarily the 
phosphodiester linkage between separate starch chains (such as monophosphates).  
 
Figure 16. Dynamic light scattering (A) and ζ-Potential (B) measurements for the various 
synthetic formulations of STMP-SNPs. There is a clear increase in particle size and negative 
surface charge with increasing STMP content in the synthesis. 
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2.2.4 Transmission Electron Microscopy (TEM) 
 
TEM is a widely-used technique to visualize nanoparticles. Samples are loaded at low 
concentration (so that there is a very thin layer of material) on to a conductive grid and placed 
into a vacuum chamber.
119
 Electrons are fired at the sample at very high energy (100-1000 kV), 
either from a thermionic (where heat is used to release electrons) or a field effect emission (using 
a strong electric field). Electrons which interact with the sample are scattered, while others are 
transmitted through to a detector and an image is generated. TEM works best with electron-dense 
samples, such as metal nanoparticles, as the scattering would be much more obvious and 
detectable. With polymeric samples, such as starch, it is more complicated. Polymer chains 
themselves would not be able to be visualized since electrons may pass straight through them, 
without any reasonable contrast to the background. In addition, the high energy electrons would 
damage the polymeric sample quite easily. This being said, there are reports of crosslinked starch 
nanoparticles being imaged by TEM, likely due to the increase in electron density.
96,98
   
TEM was performed on the STMP-SNPs at various concentrations of STMP and typical 
images are shown in Figure 17 A-F. Without STMP, small spherical particles of ca. 20 nm were 
seen. These may be due to dried appearance of the free starch chains, small droplets of oil 
remaining from the purification process, or simply an artifact of drying itself. At 1 mol % STMP, 
faint areas of darker, fibrous features indicated that there was indeed an effect on the particle 
morphology even with a small amount of STMP. Clear particles were seen beyond 5 mol% 
STMP where darker areas correspond to the dense, internally-crosslinked core of the 
nanoparticle, with lighter representing sparser crosslinking on the outer regions. These particles 
were not strictly uniform in shape but were confined between 100-700 nm in size, with isolated 
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larger (> 1 μm) and smaller (<100 nm) particles. In addition, individual chains in the crosslinked 
polymer network could be seen at higher concentrations of STMP. Based on this, it was more 
accurate to refer to this material as a nanogel as opposed to a solid particle. Since these nanogels 
were dried out for the TEM experiment, it may not necessarily reflect the solution morphology. 
This being said, the previously-obtained DLS data supports the TEM imaging, suggesting that 
the solution behaviour was not far from the dried morphology. 
 
Figure 17. TEM Images of STMP-SNPs prepared using 0 (A), 1 (B), 5(C), 10 (D), 30 (E) and 50 
(F) mol % STMP. 
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2.2.5 Environmental Scanning Electron Microscopy (ESEM) 
 SEM is another imaging technique that uses electrons to visualize samples at a much 
higher resolution than light. Unlike TEM, however, SEM relies on electrons that are scattered 
out of the sample upon bombardment rather than the electrons that are transmitted through the 
grid for contrast. The basic principle is that some electrons on the sample surface are ejected 
from the sample upon impact with the primary electron. These electrons (called secondary 
electrons) are then collected by an electric field where they hit a phosphor screen, emitting 
flashes of light. This light is then amplified using a photomultiplier tube and ultimately detected 
using digital electronics. The resulting 2-D image is a collection of intensities corresponding to 
the angle of incidence of the electrons on the surface of the sample.
120
 High incidence angles 
result in more electrons being emitted, causing steeper morphologies to appear brighter. 
Typically, this is done on conducting samples such as metals since the electrons can flow 
through the material freely without building up at the surface. If non-conducting samples (such 
as SNPs), significant charge build-up at the surface causes charging effects that significantly 
lowers the quality of the image obtained. 
A variation of this technique is environmental SEM (or ESEM), where chamber pressures 
are kept relatively high and water molecules are abundant in the sample chamber. As a result, 
charging artifacts are removed even in non-conducting samples and the image quality is 
improved.
120
 Sample preparation for ESEM is unchanged from conventional SEM. ESEM was 
performed on the 0 mol % (A) and the 10 mol % (B) STMP-SNP samples as shown in Figure 18. 
Without STMP, no obvious morphologies or particle formation was observed. However, with 10 
mol% STMP, spherical particles between 100-500 nm were observed (red arrows), consistent 
with both DLS and TEM obtained previously. It was important to note that the sample was 
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lyophilized prior to imaging with ESEM, unlike TEM where the sample was dried in air on the 
grid. This meant that the morphology obtained from ESEM would more closely reflect that in 
solution, and there would be no drying effects. Taken together with DLS and TEM results, the 
ESEM image for the 10 mol% sample suggests a uniformly spherical particle in solution. The 
size of the particle (between 100-500 nm in diameter) likely reflects the size of the emulsion 
droplets during the PIE emulsion process. 
 
Figure 18. SEM images of samples prepared without STMP (A) and with 10 mol % STMP (B) 
 
2.2.6 
31
P-NMR Spectroscopy  
 To gain an idea of the nature of the phosphate species present in the samples prepared, 
31
P NMR spectroscopy was performed. Certain atomic nuclei, when placed in a magnetic field, 
can absorb specific wavelengths of light in the electromagnetic spectrum. This is due to the fact 
that these nuclei have special spin states which will either align with or against an external 
magnetic field.
121
 For example, with a spin ½ nuclei, two spin states are present; one will align 
with the magnetic field and the other will oppose it. This generates an energy gap, the size of 
which is dependent on the specific nuclei present, and its local electronic environment. The spin 
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state of lower energy could be excited to a state of higher energy if electromagnetic radiation of a 
frequency corresponding to the characteristic energy gap was applied. This absorption of 
radiation by specific spin states in the external magnetic field forms the basis of NMR 
spectroscopy. As mentioned previously, the local electronic environment plays a major role in 
this energy gap. This is because electrons can also align themselves in the magnetic field to 
generate their own, weaker, magnetic field which opposes the external, stronger, magnetic field. 
Effectively, this shields the nuclei being probed from the external magnetic field, resulting in a 
different absorption radiation frequency. These changes are quite small, with shifts on the order 
of Hz over a MHz reference signal.
121
 As a result, the ratio of the change to the reference is on 
the order of a 10
-6
. Therefore, these values are typically multiplied by 10
6
 before analysis. This 
modified ratio is known as the chemical shift (δ) and is normally in the units of parts-per-million 
(ppm). The chemical shift can also be a negative number, as it is measured as a change relative to 
a reference frequency.
122
 
 Phosphorus (
31
P), unlike many other nuclei studied using this technique, has a spin ½ 
nuclei of 100% abundance, meaning that all phosphorus atoms could be probed using this 
technique. This being said, 
31
P-NMR, in general, is not quantitative; uneven nuclear-Overhauser 
effect (NOE) enhancement prevents any integration of the peaks.
123
 However, the chemical shifts 
can provide evidence of crosslinking within the STMP-SNPs, and the other types of phosphate 
species present. In addition, the sharpness of the peaks would indicate whether there is covalent 
attachment to the polymer chain  (broadened peaks) or whether inorganic phosphate species are 
simply embedded in the crosslinked nanogel non-covalently (sharper peaks). This reaction has 
been studied with starch, as mentioned previously.
81,82
 The data obtained from NMR was 
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compared to literature reports consistent with the chemical shifts observed for assignment of the 
peaks. 
 The 
31
P-NMR spectra for all samples prepared are shown in Figure 19 A-F. As expected, 
no organic/inorganic phosphorus species were detected for the sample prepared without STMP 
(Figure 19 A). At 1 mol % STMP (Figure 19 B), very small and poorly resolved peaks appeared 
at 0.56 and 3.53 ppm, potentially consistent with phosphodiester and monophosphate 
respectively. There was also the appearance of the outer phosphorus atoms of the starch 
triphosphate at -7.65 ppm. Based on literature, there should be a corresponding peak for the inner 
phosphorus of the triphosphate at ca. -20 ppm. However, due to the poor resolution obtained for 
this sample, this was not assigned. At 5 mol % STMP (Figure 19 C), multiple new peaks 
appeared indicative of more extensive phosphorylation. Between 0 and 5 ppm, there were 3 
peaks. Based on the particle formation from TEM imaging, some crosslinking had occurred (as 
there would be no covalent phosphodiester linkages to hold the particle together). However, it 
was not clear which of these peaks corresponded to the phosphodiester or monophosphate. In 
addition, the sharp peak at 1.33 ppm seemed to indicate an inorganic species, potentially 
inorganic monophosphate that was not removed by dialysis. In addition, 3 peaks were seen 
between -5 and -10 ppm. One of the peaks may correspond to the α and γ phosphorus atoms of 
the triphosphate, another may be the same but for inorganic triphosphate and the last one may be 
for the presence of the diphosphate. Finally, the last peak at -21.8 ppm was likely to be the β 
phosphorus of the either the organic or inorganic triphosphate. For 10 mol % STMP (Figure 19 
D), there were fewer peaks, and those that were present were quite broad. This was strongly 
indicative of only organophosphate species being present as opposed to inorganic phosphates. 
Likely, dialysis was very successful on this sample and as such, a cleaner spectrum was obtained. 
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This being said, the two peaks between 0 and 5 ppm were likely to be starch monophosphate or 
phosphodiester linkages, but it was not possible to distinguish between them. For 30 mol % and 
50 mol % (Figure 19 E and F, respectively), there was even more significant broadening of the 
peaks between 0 and 5 ppm, likely indicating significant crosslinking of starch. In addition, 
several other peaks were seen, including the outer phosphorus atoms of the organic triphosphates 
and diphosphates between -5 and -10 ppm, with sharper peaks in this region corresponding to the 
inorganic analogues to these species. At these high concentrations of STMP, it was quite likely 
that even 6 days of dialysis was not enough to remove the high amount of inorganic by-products. 
Another complication could be that the crosslinking was so extensive, that it trapped unreacted 
and inorganic species within the crosslinked nanogel, preventing escape through dialysis 
processes. 
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Figure 19. 
31
P-NMR of samples prepared with 0 (A), 1 (B), 5 (C), 10 (D), 30 (E) and 50 (F) 
mol% STMP. Overall, the nature of the species present was the same in each sample, but at 
higher concentrations of STMP, larger amounts of inorganic species were present. 
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It was important to note that while the locations of the peaks generally corresponded to 
those seen in literature (e.g. triphosphates vs. monophosphates),
81,82
 absolute assignments proved 
difficult due to the wide range of possibilities and the small differences in chemical shift between 
certain organophosphate species (e.g. phosphodiesters vs. monophosphates). Furthermore, 
chemical shifts may differ depending on which hydroxyl group in the sugar ring the phosphate 
species was bound to. To resolve these peaks definitively, it may be necessary to be break down 
the STMP-SNPs into smaller macromolecules by using enzymes (such as amylase) and 
performing 
31
P- NMR again. This would sharpen each individual peaks to a point where 
assignment could be possible. 
2.2.7 Water Retention of Nanogels 
 
 One interesting property of the prepared nanogels is their ability to retain water and 
swell, much like a macroscopic gel. In typical crosslinked nanogels, the degree of swelling is 
inversely proportional to the degree of crosslinking; a higher crosslinking density prevents the 
polymer chains from expanding in water.
124,125
 A plot of STMP concentration vs. mass of water 
retained, as well as an iodine stain of the swollen gel is shown in Figure 20 A) and B) 
respectively. Surprisingly, a significant amount of water was only retained at very high STMP 
concentration. Despite TEM images clearly showing crosslinked particles at lower 
concentrations of STMP (more specifically, 5 and 10 mol% STMP), very little water retention 
was observed. A possible explanation for this could lie in the inefficiency of the crosslinking 
reaction itself. As evident from NMR, apart from peaks attributed to crosslinking, there is a 
much higher degree of triphosphates present. It is known that the presence of charged groups 
within a crosslinked network can contribute to swelling through electrostatic repulsion.
126–128
At 
46 
 
higher concentrations of STMP, the increase in organic triphosphates could induce significant 
electrostatic repulsion within the STMP-SNPs, leading to a higher degree of swelling.  However, 
these triphosphates were not as present at low STMP concentrations (relative to monophosphates 
and phosphodiesters). As a result, there is less swelling at lower concentrations. 
 
Figure 20. Mass of water retained in nanogels prepared at different STMP concentrations (A) 
and iodine stained gels of the centrifuged product (B). In general, there was very little water 
retention at low STMP concentrations, with a significant increase at 30 mol %. 
 
 To further investigate the nature of swelling of the nanogels, the effect of salt on the 
water retention of the 30 mol% STMP-SNP sample was tested. Salts can screen the electrostatic 
repulsion within the polymer network, and potentially decrease swelling. The water retention as 
a function of salt concentration, as well as an iodine-stained image of the centrifuged 30 mol % 
STMP-SNPs as a function of NaCl concentration is shown in Figure 21 A) and B) respectively. 
For both salts, there was a significant decrease in the amount of water retained by the gel. This 
decrease was more gradual with NaCl compared to MgCl2, likely reflecting the fact that Mg
2+
 is 
a divalent ion and would more effectively screen the electrostatic repulsion than Na
+
. 
Interestingly, the swelling was not completely prevented; about 0.2 g of water was still retained 
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at high concentrations of both salts. It would be unlikely for complete dehydration of the gel to 
occur, especially to ensure that the ions stay within the polymeric nanogel.  
 
Figure 21. Mass of water retained by the 30 mol % nanogel as a function of salt concentration 
(A) and an image of the iodine-stained product with increasing NaCl concentration after 
centrifugation (B). The increase in salt concentration dramatically decreases the amount of water 
retained, with Mg
2+
 being more effective than Na
+
. 
 
2.3 Conclusion 
 
 The PIE process to make STMP-SNPs was successful based on the several 
characterization techniques performed. Firstly, the synthetic concept of phase inversion was 
confirmed from conductivity measurements, which showed a decrease in conductivity, and a 
corresponding decrease in droplet size. Once particles were purified and dried, the particle size 
and morphology varied with the amount of STMP used in the synthesis, from fibrous structures 
at low STMP concentration to clearly-defined internally-crosslinked nanoparticles at 
concentrations higher than 5 mol%. As a result, it was more accurate to call the STMP-SNPs 
“nanogels”, as opposed to a solid particle. In general, the particle size and negative charge 
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increased with increasing amounts of STMP, as evident from DLS and ζ-potential. From TEM, 
the crosslinked chains were clearly visible within the densely-crosslinked core. The 
phosphorylation of the samples was confirmed by 
31
P NMR, showing various species present 
after purification. This being said, individual peaks were not assigned as there were many 
potential possibilities. Therefore, further 
31
P NMR work needs to be done (such as spiking 
experiments and enzymatic digestion) to resolve these peaks and definitively assign them. 
Finally, the nanogels displayed swelling behaviour; a significant amount of water was retained 
upon dissolution. In general, the water retained was very low when <10 mol% STMP was used. 
It was high at 30 mol% STMP, with 50 mol% being slightly lower.  This was potentially due, in 
part, to influence from very charged phosphate groups, causing the internal phosphates to repel 
each other, leading to increased swelling. These large phosphate groups were present in greater 
amounts at higher STMP concentration. Another potential explanation lay in the inefficiency of 
the crosslinking reaction itself; only STMP concentrations higher than 10 mol% could induce 
significant crosslinking, which was reflected in the swelling characteristics. Increasing salt 
concentration also resulted in a lower amount of water retained likely due to screening of this 
electrostatic repulsion. While there was extensive characterization performed, more techniques 
(such as viscosity measurements) will need to be done in the future to further understand the 
nature of the nanogels.  
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Chapter 3. Drug Delivery Studies 
 
3.0 Introduction 
 
After successful preparation and characterization of phosphate crosslinked nanoparticles, 
the potential application in drug delivery was explored. For this purpose, confirmation was 
needed that the nanoparticles were biocompatible (not toxic to cells). This was done using an 
MTT assay. An MTT assay is normally used to determine in-vitro cell viability/toxicity. The 
MTT reagent, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium, is internalized by live cells 
and converted to a formazan by oxidoreductase enzymes, which has a strong purple colour.
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This purple colour could be quantified by absorbance at 570 nm. A strong purple colour indicates 
no cell toxicity, while a non-existent purple colour indicates high toxicity. In addition, another 
aspect of drug delivery is the ability of the nanoparticle to load and release drug. Since the 
linkage formed between the starch chains is negatively-charged (due to the phosphate group), 
there was an inherent limitation on the types of drugs that could be loaded within the crosslinked 
starched network. For example, hydrophobic drugs like docetaxel were unlikely to partition into 
the porous structure and instead precipitate out as free docetaxel. However, a positively charged 
drug (such as doxorubicin, with pKa=9.53
130
), would preferentially partition into these pores and 
load effectively. In addition, doxorubicin (DOX) is fluorescent (λexcitation=490 nm, λemission-
=590nm), and quantification of the release could be done using fluorescence-based assays. 
3.1 Materials and Methods 
 
MTT Assay. Typically, HeLa cells were seeded into 60 wells of a 96 well plate at a 
concentration of 5000 cells/well and left to proliferate (grow and divide) overnight. The next 
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day, the sample was washed with phosphate-buffered saline (PBS) and 100 μL of cell medium 
was added. At this time, 100 μL of 10 mg/mL 0 mol% STMP and 30 mol% STMP samples were 
added to the first well (final concentration 5 mg/mL) and a serial dilution was performed so that 
the next well was half the concentration of the previous well. In other words, the most 
concentrated well was 5 mg/mL, followed by the next well which was 2.5 mg/mL, and this 
dilution continued until well 9. Well 10 was reserved as a control for no sample. Since the assay 
was run in triplicates, each sample would be allocated 30 wells (10 for each series with 2 
duplicates). The cells were left to incubate with the sample overnight. The next day, 25 μL of 5 
mg/mL MTT reagent was added and allowed to be internalized into the cells for 2 hours. The 
cells were then lysed (broken apart) by pH 4.7 dimethyl sulfoxide (DMSO) to release and 
dissolve the purple formazan created in the cells. After 4 hours of incubation, the absorbance at 
570 nm was measured using a SpectraMax M3 spectrometer. The cell viability was calculated 
according the following equation: 
𝐶𝑒𝑙𝑙 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =
𝐴𝑠𝑎𝑚𝑝𝑙𝑒
𝐴𝑐𝑜𝑛𝑡𝑟𝑜𝑙
∗ 100% 
Where ASample was the measured absorbance of the sample well and Acontrol was the 
measured absorbance of the control well (without any sample). 
DOX Calibration Curve.  From a stock DOX solution of 1 mg/mL in water, several 
dilutions were made so that a final concentration of 5 μg/mL was reached. The fluorescence of 
this solution was measured using a Varian spectrometer using an excitation wavelength of 490 
nm and observing the emission peak at 590 nm. A calibration curve was generated using 5 
μg/mL as the highest concentration to 0.01 μg/mL as the lowest. A fit of the plot was found 
using linear interpolation constraining the intercept to 0. 
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Drug Loading. In a typical loading experiment, 100 μg of DOX was mixed 100 μg of 
STMP-SNPs in 1 mL of 50 mM buffer and incubated for 4 hours. After incubation, the samples 
were centrifuged to separate bound drug from loaded drug. The fluorescence of the supernatant 
at 590 nm was measured using fluorescence spectroscopy using an excitation wavelength of 490 
nm. The drug loading capacity was then calculated according to the following equation 
𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝐶𝑎𝑝𝑎𝑐𝑖𝑡𝑦 (%) =
𝐷 −
𝐹
𝑆
𝐷
∗ 100% 
Where D was the total drug added (in all cases 100 μg), F was the fluorescence of the free 
drug measured after centrifugation, and S was the slope of the calibration curve within the range 
of detection (12.454 a.u./ (μg/mL)). 
Drug Release. For drug release, STMP-SNPs were loaded at the optimal conditions 
determined from previous experiments, dispersed in 1 mL of 50 mM buffer, and placed within a 
3500 Da molecular weight cut-off dialysis membrane. The sample was then dialyzed against 19 
mL of a 50 mM buffer (Total volume= 20 mL). The fluorescence of the dialysate was measured 
using fluorescence spectroscopy. The released drug was calculated according to the following 
equation: 
𝑅𝑒𝑙𝑒𝑎𝑠𝑒 (%) =
𝐹
𝐿 ∗ 𝑆
 ∗ 𝑋 ∗ 100% 
Where F was the fluorescence intensity of the dialysate (a.u.), L was the loaded drug 
concentration (μg/mL), S was the slope (12.454 a.u./(μg/mL)), and X was the dilution factor due 
to the volume of dialysate (20). 
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Drug Release in Culture Environments. The 30 mol% STMP-SNPs (100 μg) were 
loaded with DOX to capacity in 1 mL 50 mM pH 7.6 HEPES buffer, washed three times with 
water and finally redispersed in 1 mL PBS, DMEM, 10% FBS and 100% FBS, before leaving to 
mix. The samples were centrifuged at the required time point and 10 μL of the supernatant was 
diluted to 590 μL of PBS for measurement in a Varian fluorescence spectrometer. Using the 
calibration curve, released DOX was calculated using the following equation: 
𝐷𝑂𝑋 𝑅𝑒𝑙𝑒𝑎𝑠𝑒𝑑 (%) =
𝐹
𝑆 ∗ 𝐿
 
Where F was the fluorescence of the supernatant measured by spectroscopy (a.u.), S was 
the slope of the calibration curve (a.u./(μg/mL) and L was the loaded drug concentration (for 30 
mol% STMP-SNP: 40 μg/mL). 
 
3.2 Results and Discussion 
 
3.2.1 MTT Assay 
 
 As mentioned previously, the MTT assay was used to determine if the synthesized 
particles were toxic by themselves to the cancer cells. The cell viability plots for both the 0 
mol% and 30 mol% STMP samples are shown in Figure 22.  Overall, there was very little 
toxicity seen in both samples. Though there was a noticeable decrease in the viability at 2.5 and 
5 mg/mL for the 30 mol% sample, this was also seen in the 0 mol% sample. This suggested that 
either starch itself was toxic beyond 2.5 mg/mL (though this was unlikely due to the fact that this 
was studied with BLNPs previously) or there may have been some chemicals (oil or surfactant) 
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which may not have been removed during the purification process. Another potential reason was 
the dilution of the cell medium at very high concentrations. Due to use of serial dilutions, the 
well containing the highest concentration of sample would have the lowest concentration of 
medium. This could have affected the rate of cell proliferation. In any case, this effect was not 
very pronounced and only small decreases in the cell viability were noted. Furthermore, a 
concentration of 2.5 mg/mL is already quite high for clinical applications. While many data 
points showed that there seemed to be increased cell proliferation at low concentration of 
sample, the wide error bars suggested that this effect may be due to the natural variation of cell 
proliferation in a specific well. 
0
0.0
2
0.0
4
0.0
8
0.1
6
0.3
1
0.6
3 1.3 2.5 5
0
50
100
150
C
e
ll 
V
ia
b
ili
ty
 (
%
)
Concentration of Sample (mg/mL)
 30 mol% STMP
 0 mol % STMP
 
Figure 22. MTT Assay for 0 mol% and 30 mol% samples with HeLa cells. 
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3.2.2 Drug Loading and Release 
 
Before any drug loading experiments were performed with prepared STMP-SNPs, a 
calibration curve for free DOX was generated as shown in Figure 23, showing the fluorescence 
intensity as a function of DOX concentration. In addition to being fluorescent, DOX is also quite 
coloured; at higher concentrations, inner filter effects affected the linearity of the calibration 
curve. As such, a linear fit could only be found from 0 μg/mL to 5 μg/mL.  
 
 
Figure 23. Calibration curve for DOX found by fluorescence spectroscopy. 
DOX is water-soluble, implying that if there is no loading, the drug would remain in the 
supernatant after centrifugation while the nanoparticles settle to the bottom. The drug loading for 
STMP-SNP samples prepared with 30 mol % STMP was determined at different pH as shown in 
Figure 24 A. The buffers used were: 50 mM HEPES (pH 7.6), 50 mM citrate (pH 6), 50 mM 
acetate (pH 4). Drug loading was nearly 4-fold higher at pH 7.6 compared to pH 4 or 6. This was 
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likely due to the fact that there were more phosphate groups deprotonated at higher pH, giving 
the STMP-SNPs a more negative charge. The pka of DOX (9.53) ensures that the drug is also 
quite positively charged. This means that electrostatic interactions are stronger between the DOX 
and the STMP-SNPs at higher pH, resulting in a higher loading. At lower pH, drug loading is 
limited as most phosphate groups would be protonated with the exception of the phosphodiester 
and monophosphate species. It can be concluded, therefore, that the presence of larger phosphate 
species (such as diphosphates and triphosphates) provides significant contributions to the drug 
loading. At pH 7.6, the loading capacity achieved was ~40%. This meant that for 100 μg of SNP, 
40 μg of DOX was bound. Compared to the previously-studied TEMPO-oxidized BLNPs, where 
the loading capacity was 0.05%, this represented a ~800-fold improvement in loading capacity. 
This could be attributed to the larger size of the nanoparticles, as well as the introduction of 
highly negatively charged phosphate groups which aid in the drug binding. 
Once the optimal drug loading pH was known, drug was loaded on to the starch 
nanoparticles at pH 7.6, followed by release studies using dialysis at different pH. The release 
profiles for this experiment are shown in Figure 24 B. Within the first 1-2 days for all three 
samples, there is a sharp release of drug from the nanoparticle which could be due to drug that is 
more loosely bound or due to the sharp concentration gradient between the dialysate and the 
sample. Beyond this, the released drug increases slowly with time reflecting the diffusion of the 
more tightly-bound drug. The amount of drug released was significantly greater at lower pH 
compared to that the loading pH. This could also be explained by the weaker electrostatic 
interactions between the drug and the STMP-SNP, as discussed previously. This release at lower 
pH was extremely desirable for drug delivery applications, as cancer cell interiors tend to be 
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more acidic than physiological pH. Therefore, internalization of the loaded STMP-SNPs would 
lead to a significant “burst” release in cells. 
 
Figure 24. Drug loading capacity of 30 mol% STMP-SNPs with pH (A) and drug release 
profiles of the same sample at different pH (B). For the release profile, the drug was loaded at pH 
7.6. 
 Next, the effect of STMP concentration used in the synthesis on the drug loading and 
release profiles was investigated. Evident from NMR, there is a higher amount of triphosphates 
at 30 and 50 mol% STMP relative to monophosphates compared to lower concentrations where 
monophosphates and phosphodiester linkages dominate. The drug loading capacities in 50 mM 
HEPES buffer at pH 7.6 for the various STMP-SNPs are shown in Figure 25 A. In general, the 
loading capacity increases with STMP content until 30 mol %, with a slight decrease thereafter. 
The increase in drug loading capacity is attributed to a higher concentration of phosphate species 
(especially di- and tri- phosphates) within the crosslinked nanoparticle. However, the decrease 
with the 50 mol % sample went against the trend. Since there were more available phosphates, 
there should have been a higher drug loading capacity if the drug loading was purely electrostatic 
in nature. An interesting comparison for this drug loading data was the swelling studies 
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previously performed. It was seen that with 50 mol % STMP, there was slightly less water 
retained in the nanogel compared to 30 mol %. It was quite possible that, in addition to 
electrostatic interactions, there was also significant influence from the volume of the 
nanoparticle to “store” the drug on the overall drug loading. It would also explain why there is a 
large jump in the capacity between 10 and 30 mol % STMP. 
 The release of the loaded STMP-SNPs at different STMP concentrations was monitored 
at pH 4 and the profile is shown in Figure 25 B. The sample prepared without STMP showed a 
complete burst release, implying that the drug was only loosely bound to this material. All 
samples prepared with STMP had a much more gradual release, indicating stronger drug/SNP 
interactions. There was no obvious trend in the release profile with STMP concentration. A 
minimum of drug was released (relative to the loaded drug) at 10 mol % STMP as compared to 
30 or 50 mol%, where a higher percentage was released. One possible explanation is the 
protonation of the triphosphates and diphosphates at low pH. From 
31
P-NMR, it was evident that 
there was an abundance of larger organic phosphates which contributed to the high loading, as 
discussed previously. However, in terms of release, the protonation of these groups created a 
large concentration gradient of free drug from inside and outside the dialysis membrane, 
resulting in more drug released. At low STMP concentrations, there likely were more 
monophosphates/phosphodiester linkages (relative to larger phosphate species) which bound less 
DOX, but were not deprotonated at low pH. Therefore, a lower percentage of DOX was released.  
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Figure 25. Drug loading capacity at pH 7.6 for STMP-SNPs prepared at different concentrations 
of STMP (A) and release profiles of these loaded STMP-SNPs at pH 4 (B). 
Finally, to investigate the effect of cell culture environment on the drug release, the 
loaded STMP-SNPs were placed in various environments. These included phosphate-buffered 
saline (PBS), Dulbecco’s Modified Eagle Medium (DMEM), 10% Fetal Bovine Serum (FBS) in 
DMEM, and 100% FBS. PBS is typically used as a sodium phosphate buffer formulation 
containing various salts to match physiological ion concentration, as well as pH found in blood. 
DMEM is the typical medium used for culturing many cell lines (including cancer cells) and 
contains vitamins, glucose and essential amino acids for cell growth and proliferation. FBS is the 
supernatant of centrifuged blood of a bovine fetus after adding a coagulant. This normally 
contains several proteins typically found in human blood, a major component of which is bovine 
serum albumin (BSA).  
The DOX release in these environments at 2 and 36 hours after redispersion are shown in 
Figure 26. Even for PBS, significant desorption of drug was seen after just 2 hours, even though 
the pH of this buffer was 7.4. This could be attributed to the high salt concentration (>100 mM) 
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which may have screened the attractive electrostatic interactions between the SNPs and the drug. 
In addition, the presence of the phosphates in the buffer may have attracted bound drug from the 
SNPs to the free solution. There was no major difference in the released drug after 2 hours across 
all the environments studied with ~30% of the drug released on average. After 36 hours, the 
sample incubated in 100% FBS showed complete desorption of DOX, whereas PBS had released 
~60 % of the loaded DOX. Many of the proteins in the FBS likely contain positively charged 
residues (e.g. lysine or arginine) which could effectively displace the doxorubicin from the 
SNPs. However, this likely required more time due to the proteins being more bulky than the 
salts in PBS and subsequently, steric hindrance slowed the adsorption of the proteins to the 
SNPs.  
In an ideal case, the drug would be adsorbed within the network of the STMP-SNPs such 
that larger macromolecules (such as proteins) would not be able to penetrate and displace it. 
However, it appeared that the pore size of the nanogel permitted these larger molecules to diffuse 
in, affecting the drug release. Another potential explanation was that most of the DOX was 
adsorbed only on the surface of the STMP-SNP (and not within the crosslinked network). 
Therefore, it would be much easier for the aforementioned molecules to disrupt the adsorption. 
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Figure 26. Drug release in various cell culture environments. The release was much more 
apparent in these mixtures compared to a simple buffer. 
 
3.3 Conclusion 
 
In general, the prepared STMP-SNPs were non-toxic as seen from the MTT assay. Any 
small deviation from the control did not show any specific trend, implying that the differences 
were likely due to natural variation in cell proliferation rates. This being said, a small decrease in 
cell viability was seen in both the 0 mol % and 30 mol% STMP-SNPs. This was potentially due 
to residual impurities from the PIE process or dilution of the cell medium at higher sample 
concentrations. 
Drug loading and release experiments conducted in simple environments (only buffer) 
showed significant promise. More specifically, loading capacity for the 30 mol% STMP-SNPs at 
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pH 7.6 was 40%, representing an 800-fold improvement over the BLNPs previously studied. In 
addition, the release was accelerated at lower pH, which was more desirable as cancer cell 
environments are more acidic than physiological conditions. Generally, there was increase in 
drug loading with STMP concentration used to prepare the nanogels. This reaches a maximum at 
30 mol % (~40% loading), tapering off slightly with 50 mol % (~30% loading). Curiously, this 
trend reflected the ability of the nanogels to retain water, with the highest drug loading occurring 
in the same sample which retained the water. This suggested that, in addition to electrostatic 
interactions, the swelling behaviour also influenced the drug loading within the STMP-SNPs. 
However, when loaded STMP-SNPs were placed in more typical cell culture environments, drug 
release was much quicker. It was likely that increased salt concentration, and the presence of 
proteins/other interferences caused the adsorbed drug to desorb from the nanoparticles. This 
essentially limits the nanogel usage for drug delivery applications.  
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Chapter 4. Conclusions and Future Work 
 
Nanoparticles have considerable potential in drug delivery applications. Some have 
already been implemented in a clinical setting (such as liposomes), while others have regulatory 
hurdles to cross and many are still in the early stages of investigation. Experimental grade 
BLNPs were previously provided by EcoSynthetix, a collaborating company on this project, to 
explore such applications, using DNA as an active targeting agent. In those studies it was found 
that these nanoparticles were too small; DNA aptamer coverage was scarce (resulting in low 
cellular uptake) and the drug loading was very low. Consequently, it was decided to use a food-
grade crosslinker, STMP, to increase the size of the nanoparticles through the formation of 
covalent phosphate crosslinks. The challenge lay in confining the particle size so that this 
process was not completed in bulk. To do this, an emulsion based protocol was followed based 
on a patent held by the collaborating company. In brief, a phase inversion emulsion allowed for 
sufficiently small droplet size to be formed using high shear mixing. 
  The phosphate-crosslinked SNPS (STMP-SNPs) were successfully prepared using 
different amounts of STMP during the crosslinking process. They were characterized using 
TEM, DLS and SEM. In general, the particle size increased with increasing STMP 
concentration, with more obvious nanoparticles observed at STMP concentrations higher than 5 
mol %. The STMP-SNPs were negatively charged due to phosphorylation, while the sample 
prepared without STMP was neutral, as measured from ζ-potential. The particle morphology, 
with interconnected regions of crosslinked chains suggested that these were nanogels, rather than 
solid particles. 
31
P NMR was performed on the STMP-SNPs and in general, many different 
organic phosphorus species, such as monophosphates and diphosphates, were present along with 
the phosphodiester linkages. However, enzymatic digestion of the STMP-SNPs may be 
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necessary in order to definitively resolve the peaks obtained from the spectra as significant 
broadening was present. At high STMP concentrations, the prepared nanogels retained 
significant amounts of water. This was due, in part, to the electrostatic repulsion of the larger 
phosphate species within the crosslinked polymer network. Confirmation of this electrostatic 
repulsion mechanism was found from the addition of salt to the nanogels, which significantly 
reduced the amount of water retained. 
Finally, the performance of the STMP-SNPs as a drug delivery vehicle was explored. 
Firstly, an MTT assay was used to determine any toxicity to the HeLa cancer cell line. It was 
found that the samples containing STMP did not show any significant toxicity as compared to 
the sample without STMP. For both samples, toxicity seemed to increase at 2.5 mg/mL but may 
likely have been due to either impurities from the emulsion process or medium dilution. The 
drug loading studies indicated that the model drug, DOX, was optimally adsorbed on to the 
STMP-SNPs at pH 7.6, and the loading capacity was 800-fold higher than previously-studied 
BLNPs. The release of the drug from the STMP-SNPs was much quicker at lower pH, likely 
reflecting the protonation of the phosphate species in a more acidic environment. It was also seen 
that the STMP-SNPs prepared with 30 mol% STMP had the highest drug loading, which likely 
reflected the swelling behaviour of this particular sample. 
4.1 Future Work 
 
 In terms of synthesis, it appeared that a large amount of STMP was necessary to observe 
any significant particle formation. Ideally, a low amount would be necessary; it would be easier 
to purify, as well as being more cost-effective. One potential way to improve the crosslinking 
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would be to add a divalent (or event trivalent) metal ion, in addition to the NaCl used in the 
study, as a catalyst during the PIE process.  
While extensive characterization was carried out, there remains some potential work to 
be done to fully understand the nature of the material. Firstly, viscosity measurements should be 
performed on the prepared samples to determine both molecular weight and the swell ratio. 
Ideally, the molecular weights of the STMP-SNPs would be higher than the BLNPs, as well as 
the sample prepared without STMP. The swell ratio could be used as evidence of crosslinking, 
with lower swell ratios corresponding to a higher crosslinking density. However, based on water 
retention studies, this may not necessarily be the case. Rheological experiments could also be 
conducted on the STMP-SNPs to determine the crosslinking density through measurement of the 
storage moduli. Finally, for an in-depth picture of the composition of the STMP-SNPs, 
enzymatic digestion should be performed to break down the high molecular weight particle into 
phosphorylated oligomers. This would significantly help 
31
P NMR studies and resolve broadened 
peaks for proper assignment. Since 
31
P NMR as performed was not quantitative, other methods 
could be used to determine the amount of phosphorus in the sample, such as inductive-coupled 
plasma (ICP) elemental analysis. 
 With regards to drug delivery applications, the current study suggests that DOX-loaded 
STMP-SNPs are very susceptible to drug release under typical cell culture environments. If this 
were due to simple surface attachment of the DOX to the STMP-SNPs, the problem could be 
solved by incorporating the DOX during the PIE process to ensure that it would be internalized 
in the nanogel structure.  
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 Finally, once the STMP-SNPs have been fully characterized, its cellular uptake could be 
explored. TEMPO-mediated oxidation or other methods (such as using trichloroacetate) could be 
used to convert hydroxyl groups on the STMP-SNP to carboxyl groups. Following this, 
EDC/NHS coupling could be used to conjugate dye-labelled DNA aptamer or free dyes to the 
surface of the nanogel to observe its internalization in cancer cells. 
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